![](https://news.europawire.eu/wp-content/uploads/2013/12/novartis.jpg)
Outlines actions underway to accelerate launch of Entresto®, including further expansion of US primary care field force, and reinforce strong uptake of Cosentyx® Highlights leading pipeline of second generation immuno-oncology assets Confirms Sandoz on track for 10 biosimilar filings by … Read the full press release